NuGEN Enters the Next Generation Sequencing Arena with the Ovation® RNA-Seq System
News Dec 03, 2009
NuGEN Technologies, Inc. enters the next generation sequencing (NGS) market with its Ovation RNA-Seq System, a method of sample preparation that broadens research horizons with a more comprehensive representation of the transcriptome created from samples of a few hundred picograms.
Ovation is said to be the first RNA-Seq preparation kit with no requirement for poly(A) selection or ribosomal RNA depletion. Working from total RNA reduces bias inherent in the selection steps, and leads to creation of a more complete data set - including mRNA and polyadenylated regions - for a fuller understanding of the transcriptome.
“With our wealth of expertise in sample preparation, and our track record of enabling a range of RNA and DNA analysis platforms, we enter the NGS market with a product that enhances discovery and fuels innovative research,” said Dr. Douglas A. Amorese, Ph.D., NuGEN Vice President for Research and Development.
“The Ovation RNA-Seq System is compatible with leading commercial NGS platforms and this product lets researchers ask more targeted questions with NGS, creating a whole new world of experimental opportunities for our customers.”
Prior to the launch of the Ovation RNA-Seq System, researchers were limited to working with samples of at least 1 microgram. With NuGEN’s patented Ribo-SPIA® (Single Primer Isothermal Amplification) process, in six hours researchers can transform small samples into double-stranded cDNA fragments ready for NGS analysis, the company claims.
Previous work by the International Multiple Sclerosis Genetics Consortium (IMSGC) has identified 233 genetic risk variants. However, these only account for about 20% of overall disease risk, with the remaining genetic culprits proving elusive. A new study has tracked down four of these hard-to-find genes.READ MORE